Free Trial
NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

Aclaris Therapeutics logo
$1.64 +0.07 (+4.14%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Key Stats

Today's Range
$1.57
$1.68
50-Day Range
$1.18
$1.63
52-Week Range
$1.05
$5.17
Volume
297,034 shs
Average Volume
1.20 million shs
Market Capitalization
$177.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.71
Consensus Rating
Buy

Company Overview

Aclaris Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

ACRS MarketRank™: 

Aclaris Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 643rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aclaris Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Aclaris Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aclaris Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aclaris Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aclaris Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Aclaris Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.39% of the float of Aclaris Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently increased by 54.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aclaris Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aclaris Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.39% of the float of Aclaris Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently increased by 54.75%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aclaris Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    10 people have searched for ACRS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Aclaris Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aclaris Therapeutics' insider trading history.
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
ACRS Aclaris Therapeutics, Inc. - Seeking Alpha
See More Headlines

ACRS Stock Analysis - Frequently Asked Questions

Aclaris Therapeutics' stock was trading at $2.48 at the beginning of the year. Since then, ACRS stock has decreased by 34.1% and is now trading at $1.6350.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its earnings results on Tuesday, May, 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 30.73% and a negative net margin of 732.42%.

Aclaris Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.17%). Insiders that own company stock include Braden Michael Leonard, Neal Walker, Anand Mehra, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion and Kevin Balthaser.
View institutional ownership trends
.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/06/2025
Today
7/14/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACRS
CIK
1557746
Employees
100
Year Founded
2012

Price Target and Rating

High Price Target
$16.00
Low Price Target
$6.00
Potential Upside/Downside
+455.1%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$132.07 million
Net Margins
-732.42%
Pretax Margin
-732.42%
Return on Equity
-30.73%
Return on Assets
-22.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.06
Quick Ratio
5.06

Sales & Book Value

Annual Sales
$18.72 million
Price / Sales
9.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.44 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
108,280,000
Free Float
101,351,000
Market Cap
$170.00 million
Optionable
Optionable
Beta
0.38

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ACRS) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners